Metraipolis › archive › dc_ddeab209f776
Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial — Europe PMC PMID:33735275
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/33735275
- DOI
- 10.1371/journal.pone.0248762
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-05T12:30:17.216Z
- SHA-256 of the archived text
863952c6a8bcd89eeaf920d7cd596bfc771b6026d55a2535b7bbc29c08805c4a- Stable URL of this page
https://metraipolis.com/documento/dc_ddeab209f776
How to cite
Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial — Europe PMC PMID:33735275 — Europe PMC (en), https://europepmc.org/article/MED/33735275 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_ddeab209f776 (Metraipolis archive dc_ddeab209f776, sha256 863952c6a8bcd89eeaf920d7cd596bfc771b6026d55a2535b7bbc29c08805c4a)
BibTeX
@misc{dcddeab209f776,
title = {Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial — Europe PMC PMID:33735275},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/33735275},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_ddeab209f776; sha256 863952c6a8bcd89eeaf920d7cd596bfc771b6026d55a2535b7bbc29c08805c4a},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33735275. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Purpose: Determine the cost-effectiveness of three financial incentive structures in obtaining a 1% within group drop in HbA1c among adults with diabetes. Methods: 60 African Americans with type 2 diabetes were randomized to one of three financial incentive structures and followed for 3-months. Group 1 (low frequency) received a single incentive for absolute HbA1c reduction, Group 2 (moderate frequency) received a two-part incentive for home testing of glucose and absolute HbA1c reduction and Group 3 (high frequency) received a multiple component incentive for home testing, attendance of weekly telephone education classes and absolute HbA1c reduction. The primary clinical outcome was HbA1c reduction within each arm at 3-months. Cost for each arm was calculated based on the cost of the intervention, cost of health care visits during the 3-month time frame, and cost of workdays missed from illness. Incremental cost effectiveness ratios (ICER) were calculated based on achieving a 1% within group drop in HbA1c and were bootstrapped with 1,000 replications. Results: The ICER to decrease HbA1c by 1% was $1,100 for all three arms, however, bootstrapped standard errors differed with Group 1 having twice the variation around the ICER coefficient as Groups 2 and 3. ICERs were statistically significant for Groups 2 and 3 (p<0.001) indicating they are cost effective interventions. Conclusions: Given ICERs of prior diabetes interventions range from $1,000-$4,000, a cost of $1,100 per 1% within group decrease in HbA1c is a promising intervention. Multi-component incentive structures seem to have the least variation in cost-effectiveness. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-03-18). Identificativi: PMID 33735275 · PMCID PMC7971847 · DOI 10.1371/journal.pone.0248762. Descrittori MeSH principali: Cost-Benefit Analysis. Pagina: https://europepmc.org/article/MED/33735275 — https://doi.org/10.1371/journal.pone.0248762. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-05T12:20:51.925Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.